Formycon AG
XETRA:FYB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.2
67.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Formycon AG
Formycon AG
Gross Profit
Formycon AG
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formycon AG
XETRA:FYB
|
Gross Profit
€22.9m
|
CAGR 3-Years
44%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Gross Profit
€3.2B
|
CAGR 3-Years
97%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Gross Profit
€170.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Gross Profit
-€62.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Gross Profit
€240m
|
CAGR 3-Years
26%
|
CAGR 5-Years
15%
|
CAGR 10-Years
1%
|
|
Formycon AG
Glance View
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
See Also
What is Formycon AG's Gross Profit?
Gross Profit
22.9m
EUR
Based on the financial report for Dec 31, 2023, Formycon AG's Gross Profit amounts to 22.9m EUR.
What is Formycon AG's Gross Profit growth rate?
Gross Profit CAGR 5Y
4%
Over the last year, the Gross Profit growth was 90%. The average annual Gross Profit growth rates for Formycon AG have been 44% over the past three years , 4% over the past five years .
You don't have any saved screeners yet
